RPRX Royalty Pharma Plc revenue, earnings and financials

For the quarter ended June 30, 2026, Royalty Pharma Plc reported revenue of $674M (up 16.5% from a year earlier), net income of $17.9M and diluted EPS of $0.04; over the last four quarters revenue was $2.54B and net income $812M; for the fiscal year ended December 2025 revenue was $2.38B, up 5.1% on the year before.

RPRX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $2.38B, gross profit n/a, operating income $1.56B, net income $771M (margin 32.4%), EPS $1.78
• Fiscal year ended Dec 2024: revenue $2.26B, gross profit n/a, operating income $1.29B, net income $859M (margin 37.9%), EPS $1.91
• Fiscal year ended Dec 2023: revenue $2.35B, gross profit n/a, operating income $1.49B, net income $1.13B (margin 48.2%), EPS $2.53
• Fiscal year ended Dec 2022: revenue $2.24B, gross profit n/a, operating income $307M, net income $42.8M (margin 1.9%), EPS $0.10
• Fiscal year ended Dec 2021: revenue $2.29B, gross profit n/a, operating income $1.43B, net income $620M (margin 27.1%), EPS $1.49

RPRX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $674M (up 16.5% year over year), net income $17.9M, EPS $0.04
• Quarter ended Mar 31, 2026: revenue $631M (up 11.0% year over year), net income $295M, EPS $0.67
• Quarter ended Dec 31, 2025 (from the annual report): revenue $622M (up 4.8% year over year), net income $211M, EPS $0.49
• Quarter ended Sep 30, 2025: revenue $609M (up 7.9% year over year), net income $288M, EPS $0.67
• Quarter ended Jun 30, 2025: revenue $579M (up 7.7% year over year), net income $32.2M, EPS $0.07
• Quarter ended Mar 31, 2025: revenue $568M (up 0.0% year over year), net income $239M, EPS $0.55
• Quarter ended Dec 31, 2024 (from the annual report): revenue $594M (down 0.4% year over year), net income $208M, EPS $0.46
• Quarter ended Sep 30, 2024: revenue $565M (up 5.3% year over year), net income $544M, EPS $1.21
• Quarter ended Jun 30, 2024: revenue $537M (down 0.2% year over year), net income $102M, EPS $0.23
• Quarter ended Mar 31, 2024: revenue $568M (down 17.0% year over year), net income $4.78M, EPS $0.01
• Quarter ended Dec 31, 2023 (from the annual report): revenue $596M (up 5.4% year over year), net income $494M, EPS $1.11
• Quarter ended Sep 30, 2023: revenue $536M (down 6.5% year over year), net income $72.1M, EPS $0.16
• Quarter ended Jun 30, 2023: revenue $538M (up 0.4% year over year), net income $228M, EPS $0.50
• Quarter ended Mar 31, 2023: revenue $684M (up 21.7% year over year), net income $341M, EPS $0.76
• Quarter ended Dec 31, 2022 (from the annual report): revenue $566M (down 1.7% year over year), net income −$456M, EPS −$1.04
• Quarter ended Sep 30, 2022: revenue $573M (down 2.1% year over year), net income $143M, EPS $0.32
• Quarter ended Jun 30, 2022: revenue $536M (down 3.4% year over year), net income $305M, EPS $0.70
• Quarter ended Mar 31, 2022: revenue $562M (down 1.9% year over year), net income $51.8M, EPS $0.12
• Quarter ended Dec 31, 2021 (from the annual report): revenue $576M, net income $7.90M, EPS −$0.01
• Quarter ended Sep 30, 2021: revenue $586M, net income $102M, EPS $0.24

RPRX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $2.49B, share buybacks $1.23B
• Fiscal year ended Dec 2024: operating cash flow $2.77B, share buybacks $230M
• Fiscal year ended Dec 2023: operating cash flow $2.99B, share buybacks $305M
• Fiscal year ended Dec 2022: operating cash flow $2.14B, share buybacks $0
• Fiscal year ended Dec 2021: operating cash flow $2.02B, share buybacks $0

RPRX balance sheet

• Jun 30, 2026: cash $812M, total assets $19.8B, total liabilities $10.0B, shareholders' equity n/a, long-term debt $8.58B
• Mar 31, 2026: cash $586M, total assets $19.8B, total liabilities $9.88B, shareholders' equity n/a, long-term debt $8.58B
• Dec 31, 2025: cash $619M, total assets $19.6B, total liabilities $9.91B, shareholders' equity n/a, long-term debt $8.57B
• Sep 30, 2025: cash $939M, total assets $19.3B, total liabilities $9.73B, shareholders' equity n/a, long-term debt $8.57B
• Jun 30, 2025: cash $632M, total assets $18.3B, total liabilities $8.82B, shareholders' equity n/a, long-term debt $7.00B
• Mar 31, 2025: cash $1.09B, total assets $17.6B, total liabilities $7.82B, shareholders' equity n/a, long-term debt $6.62B
• Dec 31, 2024: cash $929M, total assets $18.2B, total liabilities $7.88B, shareholders' equity n/a, long-term debt $6.61B
• Sep 30, 2024: cash $950M, total assets $18.0B, total liabilities $7.78B, shareholders' equity n/a, long-term debt $6.61B

What is RPRX's revenue?

Royalty Pharma Plc reported $2.54B of revenue over its last four quarters, through June 30, 2026.

Is RPRX profitable?

Yes. Royalty Pharma Plc earned $812M over the last four quarters.

What is RPRX's EPS?

Diluted earnings per share over the last four quarters were $1.87; $0.04 in the latest quarter.

RPRX ownership and insider trades · All stocks